![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Gemin X |
---|---|
Information provided by: | Gemin X |
ClinicalTrials.gov Identifier: | NCT00684918 |
This protocol will evaluate the efficacy of obatoclax in older patients with previously untreated AML.
Condition | Intervention | Phase |
---|---|---|
AML |
Drug: Obatoclax |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Parallel Assignment |
Official Title: | A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered For Three Consecutive Days Every 2 Weeks to Older Patients With Previously Untreated Acute Myeloid Leukemia (AML) |
Estimated Enrollment: | 106 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Experimental
In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
|
Drug: Obatoclax
A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
|
The Pilot Safety portion of the study will evaluate the safety of obatoclax administered by a 3 hour infusion for 3 days in a row. The Pilot Schedule portion of the study will randomize 16 patients in to one of two cohorts: 1) patients receiving obatoclax administered by a 3 hour infusion for 3 days in a row or 2) patients receiving obatoclax administered by a 24 hour infusion for 3 days in a row. The schedule with the best overall efficacy and safety in the Pilot Schedule portion of the study will then be utilized in the Phase II portion of the study.
Ages Eligible for Study: | 70 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have normal organ function as defined below:
Exclusion Criteria:
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60611 | |
United States, Iowa | |
The University of Iowa | |
Iowa City, Iowa, United States, 52242 | |
United States, Kansas | |
University of Kansas Medical Center Research Institute | |
Westwood, Kansas, United States, 66205 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
United States, Michigan | |
St. Joseph Mercy Hospital | |
Ann Arbor, Michigan, United States, 48106 | |
Michigan State University - Breslin Cancer Center | |
Lansing, Michigan, United States, 48910 | |
University of Michigan Health System | |
Ann Arbor, Michigan, United States, 48109 | |
United States, New York | |
St. Vincent's Comprehensive Cancer Center | |
New York, New York, United States, 10011 | |
United States, Oregon | |
Legacy Emanuel Hospital & Health Center | |
Portland, Oregon, United States, 97210 | |
United States, Pennsylvania | |
Penn State Hershey Cancer Institute-Clinical Trials Office | |
Hershey, Pennsylvania, United States, 17033 | |
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
United States, Washington | |
Benaroya Research Institute at Virginia Mason | |
Seattle, Washington, United States, 98101 | |
Canada, Ontario | |
Princess Margaret Hospital | |
Toronto, Ontario, Canada, M5G 2M9 |
Study Director: | Jean Viallet, MD | Gemin X Pharmaceuticals |
Responsible Party: | Gemin X, Pharmaceuticals ( Jean Viallet, MD ) |
Study ID Numbers: | GEM016 |
Study First Received: | May 23, 2008 |
Last Updated: | February 16, 2009 |
ClinicalTrials.gov Identifier: | NCT00684918 History of Changes |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
AML, obatoclax |
Leukemia Acute Myelocytic Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute |
Leukemia Neoplasms Neoplasms by Histologic Type Leukemia, Myeloid Leukemia, Myeloid, Acute |